Dr Toni Choueiri speaks to ecancer about all the important updates regarding kidney cancer from ASCO GU 2021. He covers many of the interesting studies seen at this year's virtual 2021 Genitourinary Cancers Symposium.

He cpvers the CLEAR study investigating sunitinib, lenvantinib everolimus and lenvantinib pembrolizumab. He then explains the response rate obtained from these drugs. He also talks about the phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC) and the efficacy results from his study.

Dr Choueiri says that there were also a lot of updates from the studies presented at ESMO 2020 and he explains what it means for the patients now.